Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP6 | P51161 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
| ▸ | PPOX | P50336 | 1/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125131 | 0.87 | FABP6 (0.67) | FABP6PARP10F7PARP1F3 | |
| SCHEMBL1887176 | 0.80 | FABP6 (0.77) | FABP6PARP10PARP1GSK3BPARP11 | |
| SCHEMBL2994247 | 0.80 | MAOA (0.58) | FABP6GSK3BKDM4EMAOB | |
| SCHEMBL12078170 | 0.80 | PARP10 (0.54) | FABP6PARP10PARP1GSK3BPARP11 | |
| SCHEMBL2061574 | 0.80 | FABP6 (0.54) | FABP6PARP10PARP1GSK3BPARP11 | |
| SCHEMBL10274616 | 0.80 | ALDH1A1 (0.56) | FABP6PARP10PARP1GSK3BPARP11 | |
| SCHEMBL16976359 | 0.79 | FABP6 (0.53) | FABP6PARP10GSK3BPARP11KDM4E | |
| SCHEMBL15525933 | 0.78 | FABP6 (0.51) | FABP6PARP10GSK3BPARP11KDM4E | |
| SCHEMBL2990086 | 0.76 | FABP6 (0.50) | FABP6GSK3BGRM5MAOB | |
| SCHEMBL18090602 | 0.76 | FABP6 (0.50) | FABP6PARP10GSK3BPARP11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042903-B1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| EP-3042903-B1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | IMPETIS BIOSCIENCES LTD (IN) | 2019-08-14 | — | — | EP | disclosed |
| EP-2838898-B1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-01-18 | — | — | EP | disclosed |
| EP-2838898-B1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-01-18 | — | — | EP | disclosed |
| EP-3042903-A1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | Advinus Therapeutics Limited (IN) | 2016-07-13 | — | — | EP | disclosed |
| EP-3042903-A1 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | Advinus Therapeutics Limited (IN) | 2016-07-13 | — | — | EP | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233983-B2 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | IMPETIS BIOSCIENCES LIMITED (IN) | 2015-03-05 | — | — | US | disclosed |
| EP-2838898-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064196-A1 | Substituted Hetero-Bicyclic Compounds, Compositions and Medicinal Applications Thereof | BTK, MALT1, LCK | FABP6 3920/4885PARP10 3813/4885F7 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.